Moderna cancer vaccine shows promising results

Moderna announced positive results from a late-stage trial of a personalized mRNA vaccine combined with Merck’s Keytruda for melanoma treatment, showing potential to extend survival and prevent cancer recurrence. The trial involved over 1,000 patients and marked a significant advancement in personalized cancer immunotherapy. If approved, this therapy could transform Moderna’s focus from infectious diseases to oncology, with broader applications in other cancers under investigation.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل